Radgocitabine

DB11667InvestigationalSmall molecule

2'-cyano-2'-deoxy-1-(beta-D-arabinofuranosyl)cytosine has been used in trials studying the treatment of Advanced Colorectal Cancer.

Mechanism: Pharmacologically active on DNA polymerase alpha catalytic subunit
Curator reviewed
Formula / weight: C₁₀H₁₂N₄O₄ · 252.23 g/mol (avg)
Code names: TAS-109

Resolves to

Compound

Structure

InChIKeyDCYBPMFXJCWXNB-JWIUVKOKSA-NSMILESNC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1C#N

Targets

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Radgocitabine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.